Failures of the latest clinical trials using focal delivery of either recombinant protein or viral vectors of GDNF (or neurturin) dampen the enthusiasm of many investigators for neurotrophic factors as PD therapeutics, as recent failed trials applied improved delivery methods and selected early to middle stage PD patients (GDNF, Parkinsons UK)13. Here, NRTN is linked to Parkinson disease.